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Abstract Introduction 12 chain community pharmacy
sites located in two geographic areas with the United States
implemented easy-to-administer memory screening
assessments for patients with risk factors of cognitive
memory decline and referred at-risk patients to their phy-
sicians. Aim of the study To evaluate the impact of a
pharmacy-based cognitive memory screening and referral
program, measure patient satisfaction with these advanced
clinical services, and assess willingness to pay for cogni-
tive memory screening services. Setting 12 chain pharmacy
sites located in two geographic areas—ten Fred Meyer
Pharmacies located in the Portland, Oregon area and two
Kerr Drug Pharmacies located in North Carolina. Method
Pharmacists were educated on Alzheimer’s disease, trained
on how to provide cognitive memory screening exams, and
equipped with screening and documentation tools. Fol-
lowing each screening, pharmacist provided education and
counseling to the patients and referred at-risk patients to
physicians for follow-up as appropriate. Main outcome
measures Results of screenings; satisfaction of patients;
willingness to pay. Results Pharmacists delivered cognitive
memory assessments to 161 patients from June to
November 2008. 44.1 % of patients experienced at least
one cognitive deficiency that required referral to a physi-
cian based on the screening conducted. The cognitive
memory screening and referral program was highly regar-
ded by patients who completed the satisfaction survey, with
98.4 % of respondents indicating that they were either very
satisfied or satisfied with the program. Conclusion Cogni-
tive memory screening can be easily incorporated into
clinical service offerings in community pharmacy practice
and provides a valuable opportunity to identify patients at-
risk and refer them to a physician for appropriate testing
and diagnosis.
Keywords Alzheimer’s disease  Ambulatory care 
Clinical pharmacy services  Cognitive memory
screening  Community pharmacy  Dementia  Physician
referral
Impact of findings on practice
• Cognitive memory screening can be easily incorporated
into clinical service offerings in American community
pharmacy practice.
Introduction
Alzheimer’s disease (AD) is a serious, progressive and
fatal type of dementia that destroys brain cells and causes
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problems with memory, thinking, and behavior. AD is the
most common type of dementia and is the sixth-leading
cause of death in the United States [1]. Almost two-thirds
of Americans with AD are women. There is no cure for
patients diagnosed with dementia, and its prevalence
increases dramatically with age. An estimated 36 million
people currently have dementia worldwide [2], including
over 5 million Americans with AD [3]. Over 115 million
people across the globe will have dementia by 2050 [2],
and in America, the number of people aged 65 years or
older with AD could increase by 50 % by 2050 [4].
Additionally, the over $600 billion international eco-
nomic impact of dementia is staggering [2]. The annual cost
to care for an American individual with dementia is $56,290
[5]. The direct and indirect financial costs to care for people
in the United States with AD amount to more than $200
billion annually, and the economic value of the care pro-
vided by family and other paid caregivers of people with AD
and other dementias is an additional $210 billion [4]. People
with AD in America have more than three times as many
hospitals stays as other older people and their total Medicare
costs were nineteen times higher than for other Medicare
beneficiaries without AD and other dementias [4].
Diagnosis of AD is complicated and can involve a com-
bination of detailed medical history, physical examination,
laboratory testing, cognitive assessments, and brain-imaging
scans conducted by a physician [3]. A definitive diagnosis of
AD can only be determined with an examination of the brain
upon autopsy. There are no treatment options to stop the
deterioration of brain cells in AD. However, there are ben-
efits of early detection, including [4]:
• early initiation of drug treatment to treat and delay the
worsening of symptoms;
• ability to engage in planning for future financial and
healthcare needs;
• engagement in support groups; and
• ability to make lifestyle changes before the disease
progresses further.
As highly accessible health care providers, pharmacists
are in an ideal position to identify and assist in the man-
agement of individuals with AD and other cognitive
memory disorders. The cognitive memory screening and
referral program (CMSRP) is the first project to measure
the impact of a pharmacist-based cognitive memory
screening service delivered in community pharmacy prac-
tice in the United States. Although community pharmacy
workflow processes may differ between the US and other
countries, this program was designed to be similar to pre-
viously implemented chronic disease screening events,
making it replicable in any setting where these types of
screening events have occurred. While the involvement of
community pharmacists in the screening of AD is novel in
the US and across the globe, there are several studies
supporting community pharmacists having a significant
beneficial role in screening of diseases. There have been
several recent examples of enhanced care through com-
munity pharmacy involvement in screening efforts both in
and outside of the US [6–9].
Utilizing a combination of self-assessment surveys,
blood tests and other biological measurements, and physical
assessments, pharmacist-provided clinical screening ser-
vices for diseases such as cardiovascular disease [10],
osteoporosis [11], depression [12], and diabetes [13] among
others have successfully improved identification of patients
at-risk, provided disease state and medication education,
and improved clinical outcomes. Some of these interven-
tions have resulted in lifestyle changes in those patients who
were identified as at-risk, highlighting the potential of
community pharmacists to improve the quality of life of the
general population [14].
Pharmacists also have a unique opportunity to identify
and assist in the management of individuals with AD. A
growing body of evidence suggests that the health of the
brain is closely linked to the overall health of the heart and
blood vessels. Some data indicate that management of
modifiable cardiovascular risk factors, such as high cho-
lesterol, Type 2 diabetes, high blood pressure, smoking,
obesity and physical inactivity may help avoid or delay
cognitive decline [15–23]. The strong link between brain
health and heart heath provides a unique opportunity for
pharmacists to expand their clinical services to provide
care to patients at-risk of developing AD and to provide
additional services to patients that are already being man-
aged by their pharmacist for other conditions.
Health education and disease awareness activities con-
sisted of a series of memory screening assessments, patient
and caregiver education, and physician referrals. The pro-
ject also included other wellness and support services in an
effort to address the spectrum of patient, caregiver and
provider needs.
Aim of the study
This manuscript describes the initial patient screening
activities, follow-up, and results of patient referrals. The
primary objective of the CMSRP was to evaluate the
impact of pharmacy-based cognitive memory screening
activities with a focus on early detection of AD, appro-
priateness of referral of at-risk patients to their primary
care physicians for potential diagnosis, and outcomes of
physician referral related to follow-up. The program also
measured patient satisfaction with advanced clinical ser-
vices and the willingness of patients to pay for cognitive
memory screening services.
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Method
The CMSRP was initiated in June of 2008 in conjunction
with 12 chain pharmacy sites located in two geographic
areas (10 community pharmacies located in the Oregon and
two community pharmacies located in North Carolina).
Within a 6-month timeframe, the participating pharmacies
screened a total 161 patients that were identified as at-risk
of developing AD.
Patient description
Services were offered to patients identified within the
community pharmacy and through awareness activities such
as posters and informational brochures, which included
information about the warning signs of AD and the avail-
ability of the screenings. Pharmacists delivered screening
services to patients by appointment, through stand-alone
screening days and through outreach to local assisted living
facilities and senior centers.
Patients were offered screening services by a pharmacist
if they self-identified as having at least one warning sign
for AD as outlined by the Alzheimer’s Association or if the
pharmacist assessed that the patient could benefit from the
service based on factors such as age, co-morbid health
conditions and/or observation of behaviors. Warning signs
for AD are listed in Table 1.
As part of the screening process, all patients and care-
givers were provided with educational information to
promote understanding of AD and maintaining brain
health. Patients were required to complete a consent form
and a health risk assessment (HRA) prior to obtaining a
cognitive memory screening from the pharmacist.
Pharmacist training
The participating pharmacists from each study site were
trained via a 2-hour live Webinar training program devel-
oped and delivered by the APhA Foundation that provided:
• An overview of the American Pharmacists Association
(APhA) Foundation CMSRP Program;
• A clinical update on AD;
• A review of the patient care process;
• A detailed overview of study forms and paperwork;
• Strategies for patient identification;
• Training on the use of memory screening instruments;
and
• A protocol review for patient follow-up, data collecting
and reporting.
Screening tools
The memory screening tools were selected based on the
ability to provide meaningful results to patients and
physicians, the ease of implementation in a community
pharmacy setting, and the small time commitment for
both the pharmacist and the patient. These tools can also
be used in conjunction with other clinical services or
educational programs that the pharmacy may already
offer (i.e., Medication Therapy Management (MTM)
services, blood pressure monitoring, or diabetes
screening).
The validated instruments used for patient screening
included the Three-Word Recall [25], the Clock Draw Test
[26], and the Animal Fluency Test [27]. The combination
of the Three-Word Recall and the Clock Draw Test is also
called the Mini-cog [28]. The Three-Word Recall tests a
patient’s ability to recall and retain information, both ele-
ments of abstract thinking. Difficulty in abstract thinking is
a component of AD. The Clock-Draw Test assesses a
patient’s ability to retain and recall pre-existing relevant
information. The scores of the Clock Draw Test are used in
conjunction with the scores of the Three Word Recall to
determine the most appropriate referral recommendation
for the patient.
The Animal Fluency Test is a categorical test or word
fluency test, which is a common and reliable type of word
recall test used to assess patients at-risk for AD or other
cognitive memory disorders [27]. Word recall tests mea-
sure short-term forgetfulness and impairment in word-
finding capability, verbal production, noun-retrieval,
semantic memory, and language.
Table 1 Warning signs for Alzheimer’s disease [24]
Warning signs for Alzheimer’s disease
Memory loss that disrupts life
Challenges in planning and problem solving
Difficulty performing familiar tasks at home, work or at leisure
Confusion with time or place
Trouble understanding visual and spatial relationships
New problems with words in speaking or writing
Misplacing things and losing the ability to retrace steps
Decreased or poor judgment
Withdrawal from work or social activities
Changes in mood or personality
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Patient counseling
Following the administration of cognitive memory
screening assessments during screening events, pharma-
cists provided counseling and disease education to patients
and caregivers as required. Counseling was customized
based on patient characteristics, medical history, medica-
tion therapy and responses to the HRA questions, and
length of counseling sessions varied based on the individ-
ual patient’s needs. Counseling elements included a dis-
cussion about the difference between screening activities
and physician diagnosis, the common reasons for cognitive
memory decline (i.e., sleep disturbances, depression, stress,
or other medications), and options for potential follow-up.
If the patient required referral to the physician, pharmacists
explained that it was for follow-up and evaluation. They
also provided the patient with a copy of the follow-up fax
to the physician if warranted.
Risk stratification and physician referral
Assessment scoring guidelines were used by pharmacists to
refer patients for physician follow-up. Mini-cog indications
for referral were used, which recommends referral for all
patients with a Clock Draw Test score of 0–3 who also have
a three-Word Recall Test score of 0–3. Patients with a Clock
Draw Test score of four and a three-Word Recall Test score
of 0 should also be referred [28]. Additionally if assessment
scores demonstrated a cognitive deficiency in any of the
three tests, patients could be referred to the physician. The
pharmacist used their professional judgment based on the
patient assessment form, medical history, screening results
and patient interaction in their decision to refer a patient for
physician follow-up. The scores for each patient assessment
and the resulting action taken by the pharmacist were doc-
umented. Patients received a verbal referral from the phar-
macist and, in cases of severe cognitive deficiency, the
pharmacist directly contacted the patient’s physician by
phone or fax to report screening results.
Main outcome measures
Results of screening
Results of screening was evaluated by identifying how
many patients pharmacists appropriately referred and did
not refer to their physicians for further evaluation, how
many patients referred planned to go to their physicians for
follow-up, and how many of those referred patients actually
followed up with their physicians. The present evaluation
did not explore other outcomes of referral such as earlier
initiation of treatment, ability to plan future financial and
healthcare needs, engage in support groups, and/or ability to
make lifestyle changes in advance of disease progression.
Patient satisfaction and willingness to pay
Patient satisfaction with services was evaluated through
two mechanisms: the completion of a voluntary participant
satisfaction survey and through follow-up phone calls from
the pharmacist to participating patients 45–90 days after
the initial pharmacy-based screening. This time frame
allowed sufficient time for patients to follow up with their
physician. Patient satisfaction surveys were provided to
patients at the time they received their screening
Table 2 Social and clinical demographics of participating patients
(n = 161)
Demographic: n (%)
Highest level of education
High school 69 (42.9)
College 55 (34.2)
Graduate school 19 (11.8)
Current living situation
Home 146 (91.8)
Assisted living 8 (5.0
Other 5 (3.1)
Family history of AD 49 (30.6)
Previous diagnosis of dementia 3 (1.9)
Previous diagnosis of stroke 16 (10)
Previous diagnosis of head injury 34 (21.4)
Risk factors of memory loss 93 (58.9)
Treated for memory loss 48 (30.4)
Table 3 Warning signs of potential memory loss (n = 161)
Warning sign n (%)
Trouble remembering names 85 (52.8)
Need reminders to do things 78 (48.4)
Misplaces car keys and other items 60 (37.3)
Forgets appointments 51 (31.7)
Repeats conversations 41 (25.5)
Family member with Alzheimer’s disease 38 (23.6)
Lost interest in hobbies and social events 35 (21.7)
Gets angry easily 32 (19.9)
Trouble finishing a sentence 30 (18.6)
Asks same questions repeatedly 29 (18.0)
Trouble reading books 23 (14.3)
Gets lost easily 18 (11.2)
Loss of smell 17 (10.6)
Has trouble making change for a purchase 6 (3.7)
Needs help eating and dressing 3 (1.9)
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assessment. A stamped and addressed envelope was pro-
vided to return the surveys to the APhA Foundation.
Patient satisfaction questions were measured on a five-
point Likert scale ranging from very satisfied to very dis-
satisfied. Follow-up phone-interviews were conducted with
patients who were referred for follow-up with a physician
to determine the outcomes of physician follow-up (i.e., if
they were prescribed medications or had additional testing)
and willingness to pay for memory screening services.
Results
The participating pharmacies identified and screened 161
patients with more than one warning sign for AD. Social
and clinical demographics in Table 2 show that of these
patients, 118 (73.8 %) were female, 124 (77.1 %) had a
high school or college education, and 146 (91.8 %) were
living at home. The mean age of participants was 65 years.
Of the 112 patients (69.4 %) that had no family history of
AD, 66 (58.9 %) had risk factors for memory loss and 46 of
those patients (69.6 %) were not being treated for memory
loss. Table 3 displays that among patients who were
identified as having warning signs of AD, the most frequent
signs reported include trouble remembering names
(n = 85, 52.8 %), needing reminders to do things (n = 78,
48.4 %), and misplacing car keys and other items (n = 60,
37.3 %).
Based on the Alzheimer’s testing scores listed in
Table 4, pharmacists identified 71 patients (44.1 %) with at
least one cognitive deficiency that required referral to a
physician based on the three screening assessments con-
ducted. Pharmacists used their professional judgment when
referring patients to their physician, referring 54 screened
patients (33.5 %) to assess the cause of cognitive memory
decline. Eight additional patients, who did not show cog-
nitive deficiencies in the screening exercises, were also
referred based on the pharmacist’s clinical judgment.
Overall, 118 patients (73.2 %) received an appropriate
recommendation by a pharmacist. An appropriate referral
recommendation included (1) patients did not qualify for
referral and therefore no physician referral was made, or
(2) referral to a physician was indicated and was made.
After receiving the pharmacist’s initial intervention, 23
referred patients (69.7 %) indicated that they planned to go
to the physician for follow-up).
Shown in Table 5, 39 patients (72.2 %) who were
referred to the physician completed the follow-up phone
survey with the pharmacist. Of those telephone survey
respondents, 22 patients (56.4 %) were willing to pay out-
of-pocket for screening services. Seventeen patients
(77.2 %) who were willing to pay indicated that they would
be willing to pay five to ten dollars for pharmacist services.
Interestingly, there was an association with willingness to








\15 animals listed 59 (36.6)







Need for referral based on three-word recall, clock draw and/or
animal fluency
Referral needed 71 (44.1)
No referral needed 90 (55.9)
Pharmacist-reported refer to MD
Yes 54 (33.5)
No 91 (56.5)
Not recorded 16 (9.9)
Extent of pharmacist referral based on need
No indication of referral, RPh referred anyway 8 (5.0)
Test indicated referral was needed, RPh did not make
referral
19 (11.8)
Referral was indicated and was made 46 (28.5)
Did not qualify for referral and no referral was made 72 (44.7)
Referral status not recorded 16 (9.9)
Table 5 Results of follow-up interviews who RPh referred and
referral was needed
Item n (%)
Follow-up with doctor (n = 33)
Patient did not go/no plan to go to doctor 10 (30.3)
Patient went/plan to go to doctor 23 (69.7)
Willingness to pay for service (n = 39)
Yes 22 (56.4)
No 17 (43.6)





Percentages based on the number of valid data available
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pay and a screening result that indicated some level of
cognitive memory decline. This exemplifies that high-risk
patients are concerned with their health, recognize the
importance of screening for health problems, and are
willing to compensate pharmacists for more accessible
services.
According to the follow-up survey, only ten patients
(21 %) who were appropriately referred by the pharmacist
followed through to see the physician within the 60 days
post study. Within that time frame, the 11 respondents
discussed the memory screening results with their physi-
cian, resulting in physicians conducting further assessment,
primarily additional testing. The lack of follow-up indi-
cates a need for more structured communications between
the pharmacists and the physician related to cognitive
memory concerns and a need to perform follow-up evalu-
ations more than 60 days after the referral was made to
identify all patients who follow-up at their next appoint-
ment with the physician.
Seventy-four screened patients (46 %) completed the
voluntary participant satisfaction survey. The CMSRP was
highly regarded by the patients who participated and
completed the satisfaction survey. Of the respondents, 73
(98.6 %) reported that they were either very satisfied or
satisfied with the program; 72 patients (97.2 %) reported
that they were either very satisfied or satisfied with the
information they received about memory and memory loss;
73 (98.6 %) were satisfied with the answers provided by
the pharmacist to any question or concerns; 73 (98.6 %)
were satisfied with the assistance of the pharmacist in the
screening program; and 73 (98.6 %) indicated that the
study pharmacy should continue to offer a cognitive
memory-screening program. The same percentage indi-
cated that they would recommend this program to family
members or friends.
Discussion
The detection of AD is difficult and without objective
markers, often making diagnosis and treatment delayed. In
a survey conducted by the Alzheimer’s Foundation of
America, AD patients experienced symptoms for roughly
2 years and saw more than one doctor before obtaining a
diagnosis [29]. Pharmacists can help to close the ‘‘patient
identification gap’’ through basic memory screening
assessments conducted in community pharmacy practice.
Early and accurate diagnosis is an important step to
ensuring the right treatment, care and support is received.
This screening program allows at-risk patients to obtain a
thorough assessment of cognitive memory decline and
facilitates a medical diagnosis from their physician.
The three assessments used in community pharmacies
are simple, straightforward and require a total of \7 min
to administer. Most community pharmacies across the
United States have similar workflow processes, which
makes this model replicable in a wide variety of US
community pharmacy practices. Just as many other
pharmacist-provided screening programs are structured,
core service elements included identification of appro-
priate patients to participate in the health screening, initial
assessment for risk factors and family history, delivery of
the screening service, patient counseling on screening
results, and referral to a physician or other health care
professional for appropriate follow-up. National organi-
zations such as the Alzheimer’s Association and the
national family caregivers Association have also devel-
oped excellent resources that can be used by pharmacists
to help educate their patients.
An important aspect for providing expanded pharmacist
services in any disease state is the potential revenue model.
As a highly accessible health care provider, pharmacists are
uniquely positioned to provide care services and commu-
nity referral resources, encourage individuals and care-
givers to take advantage of these services, and customize
pharmacy services for those with AD. The exceptionally
positive feedback from patients found in Table 5 indicates
that the pharmacist should be appropriately compensated
for these services. To ensure future sustainability of a
CMSRP, more investigation is needed that explores the
economic costs of the program relative to income
generated.
The APhA Foundation’s White Paper on Expanding the
Role of Pharmacists in Caring for Individuals with AD
concluded that increased pharmacist involvement in the
care of individuals with AD could improve clinical out-
comes and family caregiver quality of life [30]. With the
expected increase in the number of individuals diagnosed
with AD, the resources and services to care for and support
this population will be even further taxed. Maximizing the
difference pharmacists can make in the lives of those who
suffer from AD should include the continued development
of innovative approaches for pharmacist involvement in
AD, such as engaging in community awareness and
advocacy, teaching and mentoring student pharmacists and
pharmacy residents, participating in local Alzheimer’s
Associations, and publishing and presenting professional
activities.
Limitations
Of the 161 patients, 16 (9.9 %) did not have referral status
recorded on their assessment sheet. The pharmacist did
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123
not refer 19 (11.8 %) of patients whose tests indicated a
need for referral due to the interaction with the patients or
their refusal of a referral. Almost 79 % of patients refer-
red to the physician did not follow-up within 60 days
post-study. This indicates that a more effective physician
communication strategy is needed to ensure appropriate
physician follow-up for patients at-risk for AD. The
response rate of 46 % to the patient satisfaction survey
introduces potential bias to the survey results. Since the
follow-up survey was voluntary, it is possible that those
who were more satisfied with the service or those who
visited the doctor as a result, provided feedback on the
favorable experience. There is need for more research to
examine if the CMSRP model might be applicable to
other community settings both within and outside of the
United States.
Conclusion
The CMSRP was effective and valuable in identifying
patients with cognitive memory decline who could be at-
risk of developing AD and facilitating referral to their
physicians. The high percentage of referred patients that
did not follow-up with a physician underscores the
importance of team-based patient care and open lines of
communication between pharmacists and physicians.
Additionally, patients were satisfied with the services
provided by their pharmacist. Tools for the design and
implementation of a cognitive memory screening and
monitoring service in community pharmacies can be found
at www.aphafoundation.org.
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